India Liver Cancer Therapeutics Market to be dominated by Radiation Therapy through 2029
The increase in non-small cell lung cancer is
expected to drive the growth of the India liver cancer
therapeutics market during the forecast period.
According to TechSci Research report, “IndiaLiver
Cancer Therapeutics Market - By Region, Competition, Forecast, and
Opportunities, 2029”, the India liver cancer therapeutics market is
anticipated to grow at an impressive rate during the forecast period. This
can be ascribed due to the increasing use of anabolic steroids. Anabolic
steroids are masculine hormones used by certain athletes to increase their
strength and muscle mass. Prolonged use of anabolic steroids may slightly
increase the risk of hepatocellular cancer. The misuse of anabolic steroids has
been linked to several liver-related health problems, including liver damage,
liver cancer, and other liver-related diseases. Anabolic steroids are synthetic
substances that mimic the effects of testosterone in the body. They are often
used by athletes and bodybuilders to increase muscle mass, strength, and
performance. However, the misuse of anabolic steroids can lead to serious
health problems, including liver damage. Anabolic steroids are metabolized by
the liver, and prolonged use can lead to liver damage, including liver tumors
and liver cancer. Such factors will drive the growth of the India liver cancer
therapeutics market during the forecast period.
Major trend which is there in the India liver
cancer therapeutics market is collaborations and partnerships. As the market
becomes increasingly competitive and complex, companies are looking for ways to
collaborate and leverage each other's strength to drive innovation and growth.
Collaborations and partnerships can take many forms, such as joint ventures,
licensing agreements, research collaborations, and co-marketing arrangements.
For example, pharmaceutical companies may collaborate with academic
institutions or biotech startups to develop new drugs or therapies for liver
cancer. They may also partner with diagnostic companies or imaging providers to
improve early detection and monitoring of liver cancer. Collaborations and
partnerships can help companies gain access to new markets or distribution
channels. For example, a company may partner with a local distributor or
healthcare provider to expand its reach in a specific geographic region.
Challenge which is being faced by the India liver
cancer therapeutics market is lack of trained professionals, the diagnosis and
treatment of liver cancer require specialized knowledge and skills, and there
is a shortage of healthcare professionals with expertise in this area. This
shortage can lead to delays in diagnosis, incorrect treatment decisions, and
inadequate patient care. Additionally, the limited availability of trained
healthcare professionals can make it difficult to provide quality care to
patients in remote or underserved areas. Efforts are being made to address this
challenge by increasing the number of training programs and specialized courses
for healthcare professionals in the field of liver cancer diagnosis and
treatment.
Browse over XX market data Figures spread through XX
Pages and an in-depth TOC on "India Liver Cancer Therapeutics Market”
The India liver cancer therapeutics market can be
segmented by cancer type, therapy, route of administration, distribution
channel, and region. Based on route of administration, the market can be
segmented into oral, intravenous, and others. Oral route of administration is
one of the common routes used in India for liver cancer therapeutics. It
involves the use of drugs in the form of tablets or capsules that are swallowed
and absorbed in the gastrointestinal tract. Oral administration offers several
advantages, including ease of use, patient compliance, and convenient dosing
schedules. It is also a non-invasive method, which means that it does not
require injections or other invasive procedures. Some liver cancer drugs available
in India are administered orally, including sorafenib, regorafenib, and
lenvatinib. However, the choice of the route of administration depends on
various factors, such as the drug's pharmacokinetic properties, the patient's
condition, and the treatment goals. In some cases, other routes of
administration such as intravenous, intramuscular, or subcutaneous may be
preferred over oral administration.
Based on the distribution channel, the India liver
cancer therapeutics market can be segmented into hospital pharmacies, retail
pharmacies, and online pharmacies. Retail pharmacies play an important role in
the distribution of liver cancer therapeutics in India. These pharmacies are
usually located in local communities and provide access to medication for
patients with liver cancer who may not have easy access to hospital pharmacies.
Retail pharmacies can also provide advice and counselling to patients regarding
their medications and help to ensure adherence to treatment regimens. The
growth of retail pharmacy chains in India has helped to increase access to
liver cancer therapeutics in smaller towns and rural areas.
Major companies operating in the India liver cancer
therapeutics market are:
- Natco Pharma
Ltd.
- Reddy's
Laboratories Ltd.
- Intas
Pharmaceuticals Ltd.
- Mylan
Pharmaceuticals Pvt. Ltd.
- Lupin Ltd.,
Biocon Ltd.
- Hetero Labs Ltd
In 2021, Zydus Cadila Healthcare Ltd. launched a
generic version of Regorafenib, a targeted therapy drug used in the treatment
of liver cancer.
In 2021, Dr. Reddy's Laboratories Ltd. announced
that it had received approval from the DCGI to conduct Phase III clinical
trials of Sputnik V vaccine in India.
In 2019, Natco Pharma Ltd. received approval from
the Drug Controller General of India (DCGI) for its generic version of sorafenib
tosylate.
In 2016, Hetero Labs Ltd. launched its generic
version of sorafenib tosylate, under the brand name SORAFENAT, for the
treatment of liver cancer.
Download Free Sample Report
Customers can also request for 10% free
customization on this report.
“The India liver cancer therapeutics market is
expected to grow during the forecast period due to the rising demand for early
diagnosis with medical benefits along with the growing preference for
laparoscopic and robotic surgeries across the region. During the early stage of
liver cancer, the cancer is localized and has not propagated anywhere else in
the body. Therefore, to avoid further growth and spread of liver cancer, the
cancerous liver cells should be removed surgically. Besides, increasing concern
about healthy lifestyles and growing expenditure on health and wellness are
further expected to create lucrative opportunities for the growth of the
market” said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based global management consulting firm.
“India Liver Cancer Therapeutics Market,By
Cancer Type (Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma,
Angiosarcoma, and Liver Metastasis), By Therapy (Targeted Therapy, Chemotherapy
and Radiation Therapy, Immunotherapy, and Others), By Route of Administration
(Oral, Intravenous, and Others), By Distribution Channel (Hospital Pharmacies,
Retail Pharmacies, and Online Pharmacies), and By Region, Competition,
Forecast, and Opportunities, 2029” has evaluated the future growth potential of
the India liver cancer therapeutics market and provides statistics &
information on market size, structure, and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in the India liver cancer therapeutics market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com